Publicacions en què col·labora amb José Antonio Rodríguez García (72)

2024

  1. Transcriptomic Analysis of Extracellular Vesicles in the Search for Novel Plasma and Thrombus Biomarkers of Ischemic Stroke Etiologies

    International journal of molecular sciences, Vol. 25, Núm. 8

2023

  1. Role of LCN2 in a murine model of hindlimb ischemia and in peripheral artery disease patients, and its potential regulation by miR-138-5P

    Atherosclerosis, Vol. 385

2022

  1. CM-352 Efficacy in a Mouse Model of Anticoagulant-Associated Intracranial Hemorrhage

    Thrombosis and Haemostasis, Vol. 122, Núm. 8, pp. 1314-1325

  2. Lipocalin-2 and Calprotectin Potential Prognosis Biomarkers in Peripheral Arterial Disease

    European Journal of Vascular and Endovascular Surgery, Vol. 63, Núm. 4, pp. 648-656

2021

  1. Association of sdf1 and mmp12 with atherosclerosis and inflammation: Clinical and experimental study

    Life, Vol. 11, Núm. 5

  2. Molecular and Cellular Mechanisms of Delayed Fracture Healing in Mmp10 (Stromelysin 2) Knockout Mice

    Journal of Bone and Mineral Research, Vol. 36, Núm. 11, pp. 2203-2213

2020

  1. Circulating TIMP-1 is associated with hematoma volume in patients with spontaneous intracranial hemorrhage

    Scientific Reports, Vol. 10, Núm. 1

  2. Functional and transcriptomic analysis of extracellular vesicles identifies calprotectin as a new prognostic marker in peripheral arterial disease (PAD)

    Journal of Extracellular Vesicles, Vol. 9, Núm. 1

  3. MMP-10 is Increased in Early Stage Diabetic Kidney Disease and can be Reduced by Renin-Angiotensin System Blockade

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. Analysis of monocitary subpopulations in relation to cardiovascular risk factors

    Clinica e Investigacion en Arteriosclerosis, Vol. 31, Núm. 4, pp. 152-159

  2. Análisis de subpoblaciones monocitarias en relación con los factores de riesgo cardiovascular

    Clínica e investigación en arteriosclerosis, Vol. 31, Núm. 4, pp. 152-159

  3. High serum levels of tissue inhibitor of matrix metalloproteinase-1 during the first week of a malignant middle cerebral artery infarction in non-surviving patients

    BMC neurology, Vol. 19, Núm. 1, pp. 167

  4. MMP10 Promotes Efficient Thrombolysis After Ischemic Stroke in Mice with Induced Diabetes

    Translational Stroke Research, Vol. 10, Núm. 4, pp. 389-401

  5. Persistently high circulating tissue inhibitor of matrix metalloproteinase-1 levels in non-survivor brain trauma injury patients

    Journal of Critical Care, Vol. 51, pp. 117-121

  6. Trimethylamine-N-Oxide (TMAO) Predicts Cardiovascular Mortality in Peripheral Artery Disease

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Matrix metalloproteinase-10 deficiency delays atherosclerosis progression and plaque calcification

    Atherosclerosis, Vol. 278, pp. 124-134

  2. Phenotypic Screening to Discover Novel Chemical Series as Efficient Antihemorrhagic Agents

    ACS Medicinal Chemistry Letters, Vol. 9, Núm. 5, pp. 428-433

  3. Selective increase of cardiomyocyte derived extracellular vesicles after experimental myocardial infarction and functional effects on the endothelium

    Thrombosis Research, Vol. 170, pp. 1-9

2017

  1. CM352 reduces brain damage and improves functional recovery in a rat model of intracerebral hemorrhage

    Journal of the American Heart Association, Vol. 6, Núm. 6

  2. New thrombolytic strategy providing neuroprotection in experimental ischemic stroke: MMP10 alone or in combination with tissue-type plasminogen activator

    Cardiovascular Research, Vol. 113, Núm. 10, pp. 1219-1229